Hericium erinaceus mycelium ameliorate anxiety induced by continuous sleep disturbance in vivo
Journal
BMC Complementary Medicine and Therapies
Journal Volume
21
Journal Issue
1
Date Issued
2021
Author(s)
Abstract
Background: Sleep disruption is a major public health issue and may increase the risk of mortality by ten-folds if an individual is sleeping less than 6 h per night. Sleep has changed dramatically during to the COVID-19 pandemic because COVID symptoms can lead to psychological distress including anxiety. Hericium erinaceus mycelium has been widely investigated in both the in vivo studies and clinical trials for its neuroprotective functions because the mycelium contains hericenones and erinacines, which synthesize the nerve growth factor and brain-derived neurotrophic factor (BDNF). Recent in vivo reports have shown showed that erinacine A-enriched Hericium erinaceus mycelium can modulate BDNF/TrkB/PI3K/Akt/GSK-3β pathways to induce an antidepressant-like effect. A large body of evidence indicates that erinacine can pass the blood-brain barrier and suggests its neuroprotective function in both peripheral and central nervous systems. Thus, Hericium erinaceus mycelium may be a dual-function supplement for sleep disruption improvement while sustaining anxiolytic effects. Method: To simulate the condition of sleep disruption, the mice were subjected to the tail suspension test (TST) for 15 min every day during the same period for nine consecutive days. Two different doses (75 and 150 mg/kg) of Hericium erinaceus mycelium were administered orally 20 min prior to the TSTs before entering the light period of 12:12 h L:D cycle. All sleep-wake recording was recorded for 24 h using electroencephalogram and electromyogram. The elevated-plus-maze and open-field tests were conducted to record the behavior activities. Results: Consecutive TSTs prior to the light period could cause significant sleep disturbance and anxiety behavior in the elevated-plus-maze experiments. Results showed that administration with Hericium erinaceus mycelium at 150 mg/kg ameliorated the rodent anxiety (p < 0.05) and reversed the TST-induced NREM sleep disturbance in the dark period. Conclusion: This is the first in vivo study suggesting that Hericium erinaceus mycelium has a dual potential role for anxiety relief through improving sleep disruptions. ? 2021, The Author(s).
Subjects
Anxiety
COVID-19
Hericium erinaceus mycelium
NREM
Sleep
fungal extract
Hericium erinaceus mycelium extract
neuroprotective agent
unclassified drug
biological product
animal experiment
animal model
animal tissue
antidepressant activity
anxiety
Article
chemiluminescence immunoassay
controlled study
coronavirus disease 2019
dopamine blood level
electroencephalogram
electromyogram
elevated plus maze test
enzyme linked immunosorbent assay
experimental behavioral test
Hericium erinaceus
in vivo study
mouse
mycelium
neuroprotection
nonhuman
nonREM sleep
open field test
polyacrylamide gel electrophoresis
REM sleep
sensitivity analysis
signal transduction
sleep disorder
tail suspension test
Western blotting
animal
C57BL mouse
disease model
drug effect
Hericium
metabolism
sleep
Animals
Biological Products
Disease Models, Animal
Mice
Mice, Inbred C57BL
Mycelium
Sleep Wake Disorders
SDGs
Type
journal article